Philadelphia Trust Company’s Albany Molecular Research Inc AMRI Stock Holding History

Philadelphia Trust Company’s Portfolio AMRI Stock Details AMRI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-236,418	Closed	-$3.32M	–	230
2017 Q1	$3.32M	Buy	236,418 +67,318	+40%	+$1.1M	0.27%	76
2016 Q4	$3.17M	Sell	169,100 -9,175	-5%	-$156K	0.25%	79
2016 Q3	$2.94M	Sell	178,275 -3,975	-2%	-$58.9K	0.25%	75
2016 Q2	$2.45M	Buy	182,250 +2,650	+1%	+$38.7K	0.21%	76
2016 Q1	$2.75M	Buy	179,600 +26,125	+17%	+$409K	0.24%	68
2015 Q4	$3.06M	Buy	153,475 +15,025	+11%	+$286K	0.26%	66
2015 Q3	$2.41M	Buy	138,450 +135,706	+4,946%	+$2.76M	0.22%	72
2015 Q2	$136K	Sell	2,744 -120,706	-98%	-$2.33M	0.5%	53
2015 Q1	$2.17M	Buy	+123,450	New	+$2.1M	0.17%	85

Other funds holding AMRI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

American Capital Management New York $1.86B AUM 20.23% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

WIC

Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

CCM

Chicago Capital Management Chicago, Illinois $121M AUM 74.36% 1-Year Est. Return

EWM

Evercore Wealth Management New York $6.36B AUM 20.35% 1-Year Est. Return

Philadelphia Trust Company's AMRI Position: Q2 2017 in Review

Philadelphia Trust Company sold out of Albany Molecular Research Inc (AMRI) in Q2 2017, closing a stake of 236,418 shares — an estimated $3.32M sold.

Philadelphia Trust Company first reported a position in AMRI in Q1 2015 and held it in 9 quarters. The position peaked at $3.32M in Q1 2017. 136 funds tracked by Wall St. Rank hold AMRI as of Q2 2017.

Philadelphia Trust Company reported no remaining Albany Molecular Research Inc position as of Q2 2017 after selling out during the quarter.
Philadelphia Trust Company sold 236,418 Albany Molecular Research Inc shares in Q2 2017, an estimated $3.32M.
Philadelphia Trust Company first reported a position in Albany Molecular Research Inc in Q1 2015 and held it in 9 quarters.
Philadelphia Trust Company's Albany Molecular Research Inc position peaked at $3.32M in Q1 2017.
136 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q2 2017.

Based on Philadelphia Trust Company's 13F filing for Q2 2017, filed 14 Aug 2017.